Newer-generation Bruton's tyrosine kinase (BTK) inhibitors have found a place in the management of follicular lymphoma, a ...

MB-105, a CD5-targeted CAR-T cell therapy, is being evaluated in a phase 2 trial for relapsed or refractory CD5-positive T-cell lymphoma. The trial, led by Dr. Swaminathan P. Iyer, will assess ...

Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of ...

Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

FOX CHASE (WPVI) -- We often connect cancer to one part of the body. Lymphoma, however, can attack almost anywhere. But a ...

Among some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, treatment with the bispecific antibody odronextamab has been associated ...

A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings ...

A new independent academic study examining a form of blood cancer among those who served at Malmstrom Air Force Base, Montana ...

These findings suggest this unique cell therapy approach has promise for specific patients with lymphoma, but it may be adapted for more cancer types in the future. "We observed rapid and strong ...

When facing a lymphoma diagnosis, understanding the available treatment options becomes crucial for patients navigating this challenging journey. Lymphoma, a cancer affecting the immune system’s ...